Helicobacter Pylori treatment regimen and the extent of antibiotics effectiveness in AL- Gamhoria teaching Hospital and five private clinics in Aden-Yemen, 2017
Gamila Mohammed Abd

Abstract

Studies about H pylori infection in Aden governorate are still scarce. Thus, our objectives in this study are to investigate and to evaluate the incidence rate of H. pylori infection, risk factors, efficacy of therapy and drug resistance.

A cross sectional study was conducted for 325 patients who attended in Al-Gamhuria Teaching Hospital and five private clinics, in Aden governorate, during the period March to September -2017.

Gastric mucosa biopsy samples were obtained from 50 patients who had undergone upper gastrointestinal endoscopy for culture and sensitivity test for H. pylori for susceptibility to four antibiotics (clarithromycin, amoxicillin, metronidazole, and levofloxacin). During this study, we found that (70.8%) females and (29.2%) males are suffering from H. pylori infection. The maximum number of cases (41.2%) were found between the age group 21-30 years. 59.4% of them received (PPI+ Clarithromycin+ Amoxicillin or metronidazole), while 40.6% received (Levofloxacin containing triple therapy) for 10-14 days.

25.2% have been completely improved, and 3.4% haven’t, while 30.2% have recurrent, 41.2% not return for farther follow up. All risk factors are in higher percentage.

The commonest drug resistant for Amoxicillin was 30%, Clarithromycin 26% and metronidazole was 24%, while 20% for Levofloxacin.

Conclusion:- To eradicate H. pylori successfully, the whole society authorities and systems should cooperate together as one team because this is multifactor problem, including host, environmental, socioeconomic, educational and inappropriate treatment.

Keywords: Antibiotics, H. Pylor, Drug resistance, Aden.

Introduction:-

In order to prevent the disease progression, it is important to concentrate our efforts on the eradication of H. pylori, by using the gold standard therapy, first line (Triple regimen), combining of (PPI) with two antibiotics (clarithromycin and amoxicillin or metronidazole).[15,4]

But the misuse and overuse of antimicrobials recently lead to drug resistance, which explains the reason behind triple therapy failure. [9]

So, the appearance of antibiotic resistance which lead to decrease the eradication rate (70-85%) [9,12], is the main reason for treatment failure. [13,14] Therefore, many patients require second-line therapy. [10]

The management of H. pylori has become a challenge for physicians due to increase in an antimicrobial resistance[12] so, Levofloxacin-containing triple therapy for 7-10 days has been used as another option in Europe. [8]

In our consideration, prophylaxis is better than treatment, specially in our country where people are very poor and the treatment regime contains many drugs and cost a lot of many. In addition in the last years infection with H. Pylori increased too much due to deterioration of socioeconomic, bad sanitary conditions and low cultural education.
Objectives:
The objective of present study is to investigate and to evaluate the incidence rate of H. pylori infection, risk factors, efficacy of therapy and drug resistance, in Aden Governorate.

Materials and Methods:
A cross-sectional study was performed in AL-Gamhuoria Teaching Hospital and five private clinics from March –September 2017, in Aden Governorate.
Data were gathered by using direct interview with patients, who were randomly selected. The total number of patients in this study was 325.
A questionnaire containing questions about patients history such as (age starting from 10 years’ old up to more than 50 years old, sex, sanitary condition, risk factors) was prepared. Another questionnaire that deals to drugs (type of drug, dosage, duration, and effectiveness of therapy) was also used. All patients received first line therapy for 10-14 days.
Gastric mucosa biopsy samples obtained from 50 patients who had undergone upper gastrointestinal endoscopy were cultured for H. pylori, and susceptibility to four antibiotics (clarithromycin, amoxicillin, metronidazole, and levofloxacin).
Data were processed using computer. Percentage was used as summary measure and the results are presented in tables (1-6). Data analysis was obtained by using the SPSS (18 version) program.

Ethical Consideration: To perform this study we obtained the agreement of all patients.

Results:

| Age          | Frequency | %   |
|--------------|-----------|-----|
| 10-20 years  | 38        | 11.7|
| 21-30 years  | 134       | 41.2|
| 31-40 years  | 60        | 18.5|
| 41-50 years  | 40        | 12.3|
| More than 50 years | 53   | 16.3|
| Total        | 325       | 100 |

The highest percentage of age is 21-30 years (41.2%)

| Sex          | Frequency | %   |
|--------------|-----------|-----|
| Males        | 95        | 29.2|
| Females      | 230       | 70.8|
| Totals       | 325.5     | 100 |

The female sex shows the commonest percentage (70.8%)
Table 3: Distribution of patients according to drug uses

| First line therapy | Frequency | %     |
|--------------------|-----------|-------|
| PPI Clarithromycin | 193       | 59.4  |
| PPI Clarithromycin | 132       | 40.6  |
| Total              | 325       | 100   |

The highest percent (59.4%) was with PPI and Amoxicillin, or Metronidazole

Table 4: The effectiveness of antibiotic therapy

| Improvement            | Frequency | %     |
|------------------------|-----------|-------|
| Improved               | 82        | 25.2  |
| Not Improved           | 11        | 3.4   |
| Recurrent              | 98        | 30.2  |
| Patients not return    | 134       | 41.2  |
| Total                  | 325       | 100   |

This Table Shows the highest percent 41.2% who haven’t return for further follow up, while 30.2% of patients have recurrent

Table 5: Incidence of patients according to risk factors

| Risk factor          | Yes      | No   | Total |
|----------------------|----------|------|-------|
| Spicy food           | 68.3%    | 31.7%| 100%  |
| Emotional stress     | 75.4%    | 24.6%| 100%  |
| Family history       | 66.5%    | 33.5%| 100%  |
| Overcrowded          | 71.2%    | 28.2%| 100%  |
| Eat fast food        | 73.2%    | 26.8%| 100%  |
| Bad sanitary conditions | 62.1% | 47.9%| 100%  |

All risk factors are in higher percentage
Note: each factor is calculated from the total number of cases (325).

Discussion of Pylori:

If H. pylori infection untreated during childhood, it can persist lifelong, due to risk factors which reduce immunity and keep the causative organism persist for longer time. Even if individuals living in the same country, there are different factors that play major role in H. pylori infection, such as ethnicity, place of birth, socioeconomic class and environmental, cultural and educational factors.[19]

From the results that shown in Table 1, the commonest age group was between 21-30 years (41.2 %), most of them are students in university who have no time for regular eating and most of their food are fast food. The students are also always under stress of studying process. In some studies, was found that H-pylori infection more common above 40 years.[19]
**Helicobacter Pylori treatment regimen and the extent**

Gamila Mohammed Abdo

Females are commonly infected than males 70.8% as seen in Table 2, and this is mainly because the female in our country are continually under stress due to heavy load of big family, deterioration of socioeconomic condition, people always live under stress, fear and many problems, especially after war. Also the total number of females in this study is two thirds, while that of males was one third.

Previous studies, showed no significant difference in H. pylori prevalence according to gender. The male-to-female ratio is in concordance with the study done by Tarkhashvili et al. [22], and Shokrzadeh et al. [20] but these results are in contrast with a study done by Kaore et al. [11] which showed higher prevalence in male gender.

The triple regimen combination of proton pump inhibitor (PPI) with two antibiotics (Clarithromycin + Amoxicillin or metronidazole), is currently considered the gold standard therapy for eradication of Pylori [4,15].

The increasing in antibiotics resistance affected inversely eradication rate [13,14] to reached up to (70-85%), [15].

Table 3 shows that 59.4% of patients have used first line therapy including proton pump inhibitor (PPI) and two antibiotics (Clarithromycin + amoxicillin or metronidazole), for 10-14 days, while 40.6% have used first line levofloxacin-containing triple therapy for 10-14 days, which have been use as another option in Europe [8].

Inappropriate treatment, host, environmental, socioeconomic, cultural and educational factors all these play a major role in the falling rate of eradication therapy [16].

Table 4 showed 25.2% of patients are improved by using the therapy, while 3.4% are still have the same complain, 30.2% have recurrent symptoms may be due to poor compliance, lack of emphasis on eradication therapy or may be due to drug-related adverse effect. 41.2% are never return again for further follow-up, these last groups may be improved, but not return due to too far living condition, or may not be improved, and the patients feel depressed because he or she needs to improve so fast, this is due to socioeconomic and sociocultural education condition in our country. These types of patients formed the source of drug resistance, and treatment failure, and make a challenge for physician to have persuade the patients to follow the treatment regimen completely [1].

All patients in this study show high risk factors including emotional stress75.4%, fast food73.2%, 71.2% overcrowded families, this facilitate the transformed the diseases from patient to healthy one, family history66.5 and bad sanitary condition 62.1% as seen in Table 5.

The eradication rate is influenced by multiple factors include mechanism of resistance in H. pylori ,hosts, environmental and other factors that are not completely understood [1,3,7,21,23,24].

Culture and sensitivity test for antimicrobial drugs for 50 patients were done, the results are the following: 30% are resistance to amoxicillin, and 26% to clarithromycin the essential factor for amoxicillin and clarithromycin resistance is previous consumption of these antibiotics during all childhood period, where the children are frequently sick, by UPRI.

European studies, performed at the past 6 years intervals reported that H. pylori resistance was decreased from 36.65% in 2009 to 24.38% in 2014. In Asian regions, a surprising clarithromycin resistance frequency was reported from India (58.8%) and China (46.54%), whereas the lowest rate was discovered in Malaysia (2.4%). [2,6,16].

Twenty four percent was the resistance to metronidazole, as well as metronidazole has commonly been used in our country for aemobiasis, giardiasis, genitourinary tract infection which are common infections [4,15,17].

Researchers reported that the rate of treatment failure is more than 20% with triple therapy in which metronidazole is the drug of choice, also H. pylori resistance to metronidazole is the chief solitary reason responsible for management failure [5,18].

In our study, twenty percent of patients are resistance to levofloxacin in our study, as levofloxacin become widely used, in eradication therapy. A high rate of drug resistance has arisen against it.

A study in China showed that the levofloxacin resistance rate was 20.6%, due to the dramatic increase in clarithromycin resistance. Levofloxacin, a wide spectrum quinolone, has been used as...
Helicobacter Pylori treatment regimen and the extent …………..Gamila Mohammed Abdo

an alternative of clarithromycin in some regimens. But the frequent use of quinolones for urinary tract infections has increased the incidence of H. pylori resistance in the world. [6]

Conclusion

To eradicate H. pylori successfully, the whole society authorities and systems should cooperate together as a team. Physicians should not focus only on treatment regimen, patient education and elevate level of awareness is one important role of physician as well, besides, individual treatment plan is required according to patients’ varieties and medical history. The educational information are crucial to ensure treatment compliance and successful eradication of H. pylori. Sanitation and hygiene procedures applied by the governmental and socioeconomic sectors play a major role to reduce H. Pylori infection, social support system will encourage the patient to follow the treatment and help to prevent further infection or relapse.

References:
1-Bode G, Mauch F, Malfertheiner P. (1993) The coccoid forms of Helicobacter pylori. Criteria for their viability. Epidemiology Infect. 111:483–490. [PMC free article] [PubMed]
2-Boltin D, Ben-Zvi H, Perets TT, Kamenetsky Z, Samra Z, Dickman R, Niv Y. (2015) Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014 has the tide turned? J Clin Microbiol. 53:522–527. [PMC free article] [PubMed]
3-Broutet N, Thamgoué S, Pereira E, Lamouliatte H, Salamon R, Méraud F.(2003) Risk factors for failure of Helicobacter pylori therapy--results of an individual Data analysis of 2751 patients. Aliment Pharmacol Ther. 17:99–109. [PubMed]
4- Chey WD, Wong BC.,(2007). American College of Gastroenterology guideline on management of Helicobacter pylori infection. Am J Gastroenterol 102:1808–25.
5-Dumann HG, Fölsch UR, Hahn EG, von Kleist DH, Klör HU, Kirchner T, Strobel S, Kist M.(2000). Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. Helicobacter. 5:41–51.[PubMed]
6-De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. (2010). Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 19:409–414.[PubMed]
7-Gasparetto M, Pescarin M, Guariso G.(2012). Helicobacter pylori Eradication Therapy: Current Availabilities. ISRN Gastroenterol. 2012:186734. [PMC free article] [PubMed]
8- Gisbert JP, Morena F. (2006). Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 23:35–44.
9-Graham DY, Shiotani A(June 2008). New concepts of resistance in the treatment of Helicobacter pylori infections. Nature Clin Pract Gastroenterol Hepatol 2008; 5(6): 321-31. doi:10.1038/ncpgasthep1138. PMC 2841357. PMID 18446147.
10-Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153. [PubMed]
11-Kaore NM, Nagdeo NV, Thombare VR. (2012). Comparative evaluation of the diagnostic tests for Helicobacter pylori and dietary influence for its acquisition in dyspeptic patients: A rural hospital based study in central India. JCDR. 6:636–41.
12-Kim BG, Lee DH, Ye BD, Lee KH, Kim BW, Kim SG, Kim SW, Kim SK, Kim JJ, Kim HY . (2007). Comparison of 7-day and 14-day proton pump inhibitor- containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter. 2:31–35. [PubMed]
13- Kim JM, Kim JS, Jung HC. (2004). Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother. 7–48;4843;
Helicobacter Pylori treatment regimen and the extent

14- Kim N, Kim JM, Kim CH.(2006). Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol. 40:683–7.
15- Malfertheiner P, Megraud F, O’Morain C. (2007). Current concept in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 56:772–81.
16- Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. (2013). Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–[PubMed].
17- Megraud F.(2004). Helicobacter pylori antibiotic resistance: prevalence, importance and advances in testing. Gut. 53: 137-84.
18-Mégraud F, Lamouliatte H.(2003). Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 17:1333–1343. [PubMed].
19- Pounder RE, Ng D (1995). "The prevalence of Helicobacter pylori infection in different countries". Aliment. Pharmacol Ther. 9 (Suppl 2): 33–9. PMID 8547526
20-Shokrzadeh L, Baghaei K, Yamaoka Y, Shiota S, Mirsattari D, Porhoseingholi A. (2012). Prevalence of Helicobacter pylori infection in dyspeptic patients in Iran. Gastroenterol Insights. 4:24–7.
21-Song HY, Li Y.(2013). Can eradication rate of gastric Helicobacter pylori improved by killing oral Helicobacter pylori? World J Gastroenterol. 19:6645–6650. [PMC free article] [PubMed]
22-Tarkhashvili N, Beriashvili R, Chakvetadze N, Moistsrapishvili M, Chokheli M, Sikharulidze M. (2009). Helicobacter pylori infection in patients undergoing upper endoscopy, Republic of Georgia. Emerg Infect Dis. 15:504–5.
23- Wermeille J, Cunningham M, Dederding JP, Girard L, Baumann R, Zelger G, Buri P, Metry JM, Sitavane R, Gallaz L. (2002). Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin. Biol. 26:216–219. [PubMed]
24- Zhang M, Zhou YZ, Li XY, Tang Z, Zhu HM, Yang Y, Chhetri JK.(2014). Seroepidemiology of Helicobacter pylori infection in elderly people in the Beijing region, China. World J Gastroenterol. 20:3635–3639.[PMC free article] [PubMed]
علاج جرثومة المعدة ومدى فعالية المضادات الحيوية في العيادات الخارجية في محافظة عدن 2017

جميلة محمد عبده سعيد
كلية الصيدلة، جامعة عدن

DOİ: https://doi.org/10.47372/uajnas.2020.n1.a24

المؤخَّر

تهدف هذه الدراسة لمعرفة مدى انتشار مرض جرثومة المعدة والعوامل المساعدة لذلك، ومدى فعالية المضادات الحيوية في علاجها. وقد تم دراسة 325 مريضاً تم اختيارهم بطرق عشوائية من العيادات الخارجية لمستشفى الجمهورية التعليمي وخمس عيادات خاصة في الفترة من مارس إلى سبتمبر 2017. كما تم أخذ عينات من غشاء المعدة لخمسين مريضاً في أثناء عمل المناظر لفحصها لمعرفة مدى فعالية المضادات الحيوية، ومدى مقاومة البكتيريا لها.

والتقى النتائج كما يأتي:

1- عدد النساء المصابات بالمرض (70.8%) بينما عدد الرجال (29.2%)، حيث كانت الفئة العمرية الأكثر اصابة بين (30-21 سنة) بنسبة (59.4%).

2- كانت نسبة المرضى الذين تتحسن مع استخدام المضادات الحيوية (25.2%)، بينما (3.4%) لم يتحسنوا، ولا يزال البعض يعاني من تكرار وجود الأعراض، وهم (30.2%)، وهناك عدد كبير من المرضى لم يعودوا للاستلام (41.2%).

3- كانت نسبة مقاومة البكتيريا للمضادات الحيوية كالتالي: (30%) مقاومة للأموكساسيلين (Amoxicillin)، (26%) مقاومة للكلاريثرومايسين (Clarithromycin)، (24%) للمرنيدازول (Metronidazole)، (20%) مقاومة لليفوفلوكساسيلين (Levofloxacin).

ولناظِرًا لوجود عوامل عديدة متداخلة ومترابطة ببعضها البعض أدت إلى زيادة انتشار المرض، وأيضاً كثرة استخدام المضادات الحيوية بدون وجود وصفة طبية، وللحد من انتشار المرض، والعمل على التخلص منه يتطلب من جميع العامل المسؤول والجادة كلا حسب موقعه وقدره، المريض، الطبيب، وزارة الصحة، والعاملين في الخدمات الصحية وجميع أفراد المجتمع.

الكلمات المفتاحية: جرثومة المعدة، مقاومة البكتيريا، المضادات الحيوية، مدينة عدن.